Skip to main content

Table 3 Effects of treatment on LV dimensions and function

From: Potential advantages of cell administration on the inflammatory response compared to standard ACE inhibitor treatment in experimental myocardial infarction

-1 days 0 days # 7 days 14 days
  UT ACE-I BMMNCs UT ACE-I BMMNCs UT ACE-I BMMNCs UT ACE-I BMMNCs
LAd mm 2.3 ± 0.2 2.2 ± 0.2 2.2 ± 0.3 3.2 ± 0.3 2.7 ± 0.4* 3.1 ± 0.4 3.4 ± 0.2 2.7 ± 0.4** 3.1 ± 0.3 3.5 ± 0.3 2.7 ± 0.4* 2.6 ± 0.6*
LVEDd mm 5.0 ± 0.5 5.1 ± 0.1 5.1 ± 0.2 5.5 ± 0.5 5.2 ± 0.2 5.4 ± 0.3 5.5 ± 0.7 5.3 ± 0.2 5.4 ± 0.2 5.6 ± 0.7 5.4 ± 0.2 5.3 ± 0.3
E/A 3.9 ± 0.1 3.9 ± 0.1 3.8 ± 0.1 3.7 ± 0.5 3.6 ± 0.4 3.3 ± 0.3 3.5 ± 0.4 3.6 ± 0.5 3.0 ± 0.3 3.4 ± 0.5 3.4 ± 0.6 2.6 ± 0.4
FS % 50.1 ± 1.0 50.2 ± 2.5 49.9 ± 1.7 39.9 ± 4.8 47.4 ± 3.5** 42.2 ± 3.8 38.0 ± 3.6 46.8 ± 3.6** 39.6 ± 3.6§ 37.4 ± 3.4 45.3 ± 3.6** 43.5 ± 3.9*
EF % 80.0 ± 0.8 81.9 ± 3.4 81.8 ± 1.3 71.8 ± 5.5 80.1 ± 3.1** 76.4 ± 4.6 71.7 ± 5.2 81.3 ± 3.6** 77.8 ± 4.4 72.2 ± 4.8 81.1 ± 3.6** 77.8 ± 4.1
  1. LAd = Left Atrial Diameter; LVEDd = Left Ventricular End Diastolic Diameter; E/A = ratio between the velocities of E and A waves of the mitral diastolic flow; FS = Fractional Shortening.
  2. # data on day 0 refer to echocardiograms performed 6–24 hours from injury.
  3. *p = 0.05 vs UT ; **p = 0.01 vs UT; §p = 0.01 vs ACE-I